Shattuck Labs(STTK)

Focus: Shattuck Labs is a public-stage immunotherapy platform company focused on oncology, headquartered in Austin, TX. The company is in early-stage clinical development with a portfolio of Phase 1 programs.

Oncology

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Shattuck Labs

AI assessmentNot Hiring

No open roles listed right now. Follow Shattuck Labs to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$6M

Pipeline & Clinical Trials

SL-172154

Ovarian Cancer

PHASE_1

Clinical Trials (1)

NCT04406623Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer

Phase 1

Help build intelligence for Shattuck Labs

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides equity liquidity and potential upside if pipeline programs advance — meaningful for wealth creation
Focused immunotherapy platform with multiple oncology shots on goal (6 Phase 1 programs) across diverse indications
Austin-based location offers lower cost-of-living than San Francisco/Boston biotech hubs with emerging innovation ecosystem

Watch Out For

Extremely early-stage pipeline: all 6 programs are Phase 1 with no Phase 2+ catalysts near-term — multi-year, high-attrition risk ahead
Severe burn rate ($67M R&D spend on $6M revenue) with only $57M cash (FY2025) signals potential need for capital raise or restructuring within 12-18 months
Minimal hiring momentum: only 1 active role despite being public — suggests constrained growth or execution challenges

Generated by Claude from Shattuck Labs's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Drug: SL-172154

Cutaneous Squamous Cell Carcinoma

PHASE_1

Clinical Trials (1)

NCT04502888Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin

Phase 1

SL-172154

Acute Myeloid Leukemia

PHASE_1

Clinical Trials (1)

NCT05275439Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

Phase 1

SL-279252

Squamous Cell Carcinoma of the Head and Neck

PHASE_1

Clinical Trials (1)

NCT03894618SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Phase 1

Pegylated Liposomal Doxorubicin + SL-172154

Platinum-resistant Ovarian Cancer

PHASE_1

Clinical Trials (1)

NCT05483933Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Phase 1

SL-325

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT07158437Phase 1 Study of SL-325 in Healthy Volunteers

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 6 clinical trials

Top TAs: Oncology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

5 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$6M245%

R&D Spend

$67M(1175%)10%

Net Income

-$75M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles